Immunic AG – Home

Immunic is a specialist in selective oral drugs in immunology and focused on developing novel oral therapies with best-in-class potential for chronic inflammatory and autoimmune diseases.


Immunic is based in the Munich biotech hub Martinsried, Germany, and has subsidiaries in Halle/Saale, Germany, and Melbourne, Australia. The company currently develops three products for the treatment of chronic inflammatory and autoimmune diseases including e.g. inflammatory bowel disease and psoriasis. IMU-838 is currently being tested in a phase 2b trial in patients suffering from ulcerative colitis. Additional phase 2 trials in patients with Crohn’s disease, multiple sclerosis and primary sclerosing cholangitis are planned for 2019. IMU-935 is a best-in-class inverse agonist of the nuclear receptor RORγt and currently in preclinical development. IMU-856 is a newly developed and orally available small molecule aiming at a yet undisclosed target and currently in preclinical testing.

Immunic Therapeutics to Present at the BIO CEO & Investor Conference on February 11

Planegg-Martinsried, Germany, February 6, 2019 – Immunic AG (Immunic), a privately-held clinical-stage biotechnology company, today announced that Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will present at the BIO CEO & ...
Read More

Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company

San Diego, CA, USA and Planegg-Martinsried, Germany, January 7, 2019 – Vital Therapies, Inc. (Nasdaq: VTL), and Immunic AG (Immunic), a private clinical-stage biotechnology company in Planegg-Martinsried, Germany, today announced that they ...
Read More

Immunic enters into a global option and license agreement with Daiichi Sankyo

Immunic AG gains exclusive, worldwide rights to promising drug development program with novel target for treatment of inflammatory bowel disease Planegg-Martinsried, Germany, November 5th, 2018 – Immunic AG (Immunic Therapeutics), ...
Read More